LINCOMYCIN HCL (lincomycin hydrochloride) by Pfizer is mechanism of action lincomycin inhibits bacterial protein synthesis by binding to the 23s rna of the 50s subunit of the bacterial ribosome. Approved for the treatment of serious infections due to susceptible strains of streptococci, pneumococci, staphylococci and 2 more indications.
Drug data last refreshed 1mo ago
Mechanism of Action Lincomycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the bacterial ribosome. Lincomycin is predominantly bacteriostatic in vitro .
Worked on LINCOMYCIN HCL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Relative Bioavailability Study Of Two Lincomycin Hydrochloride Hard Gelatinous Capsule
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo